Search clinical trials for: Asunaprevir, Daclatasvir, Ribavirin and Peginterferon alfa-2a

Total 891 results

ANRS, Emerging Infectious Diseases
Bristol-Myers Squibb

Completed

Pilot Study to Assess the Efficacy of and Tolerance to a QUadruple Therapy to Treat HIV-HCV Coinfected Patients Previously Null Responders (QUADRIH)

HCV-HIV Co-Infection

France
Bristol-Myers Squibb

Completed

Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha and Ribavirin)

Hepatitis C Infection

United States, France
Chugai Pharmaceutical

Completed

A Study of Peginterferon Alfa-2a in Combination With Ribavirin in Patients With Chronic Hepatitis C

Chronic Hepatitis C
Bristol-Myers Squibb

Completed

Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives) (Hallmark DUAL)

Hepatitis C Virus

France, Germany, Korea, Republic of, Spain, Taiwan, United States, Canada, Australia, Russian Federation, Austria, Israel, Italy, Netherlands, Argentina, Poland, United Kingdom, Ireland, New Zealand
Májbetegekért Alapítvány
Hoffmann-La Roche

Unknown

Continuing Treatment With Pegasys and Copegus

Chronic Hepatitis C

Hungary
Hospital Clinico Universitario San Cecilio

Completed

Efficacy and Safety to Extend Treatment 24 Weeks in co-Infected HIV-HCV Genotype 1 and/or 4

HIV Infections | Hepatitis C

Spain
Bristol-Myers Squibb

Completed

Efficacy and Safety Evaluation of a Regimen Consisting of Peginterferon Lambda-1a + Ribavirin + Daclatasvir (Lambda + RBV + DCV) in HCV Genotype 1b Treatment naïve Patients or Prior Relapsers to Peginterferon Alfa + Ribavirin (Alfa + RBV) Therapy (STRUCTURE)

Hepatitis C

France, Germany, Italy, Japan, Korea, Republic of, Russian Federation, Taiwan, United Kingdom, United States, Spain, Israel, Argentina, Poland
Hoffmann-La Roche

Completed

A Study of Ribavirin in Combination With PEGASYS (Peginterferon Alfa-2a (40KD))in Patients With Chronic Hepatitis C

Hepatitis C, Chronic

Russian Federation
National Taiwan University Hospital
Hoffmann-La Roche

Unknown

Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C/Hepatitis B Co-Infection and Chronic Hepatitis C

Hepatitis C, Chronic | Hepatitis B, Chronic

Taiwan
Bristol-Myers Squibb

Withdrawn

Efficacy and Safety Evaluation of a Treatment Consisting of Peg Interferon Alfa + Ribavirin + Daclatasvir in HCV Genotype 1 and 4 Treatment naïve Patients (COMMAND-Asia)

Hepatitis C
Hoffmann-La Roche

Completed

A Study Evaluating Slow Response/Non-Rapid Response in Patients With Chronic Hepatitis C, Genotype 1, 2, 3 & 4 Treated With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)

Hepatitis C, Chronic

Israel
Hoffmann-La Roche

Completed

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Ribavirin in Hemophiliac Patients With Chronic Hepatitis C.

Hepatitis C, Chronic

Mexico
Hoffmann-La Roche

Completed

POTENTE Study: A Study of Early Virological Response in Naive Patients With Chronic Hepatitis C, Genotype 2 or 3, Treated With PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Copegus (Ribavirin).

Hepatitis C, Chronic

Brazil
Vertex Pharmaceuticals Incorporated

Completed

Phase 2 Study of VX-950, Pegasys and Copegus in Hepatitis C

Hepatitis C

United States, Puerto Rico
Vertex Pharmaceuticals Incorporated

Terminated

A Safety and Efficacy Study of the Combination of VX-222 and Telaprevir in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus Infection

Chronic Hepatitis C Virus Infection

United States, New Zealand
Hoffmann-La Roche

Completed

A Study of RO5024048 in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 1 or 4

Hepatitis C, Chronic

United States, Canada
Hoffmann-La Roche

Completed

A Study of Sustained Virological Response in Relation to IL28-b Expression in Treatment-Naïve Patients With Chronic Hepatitis C Genotype 1 on Combination Treatment With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)

Hepatitis C, Chronic

Brazil
Chugai Pharmaceutical

Completed

A Study of Peginterferon Alfa-2a in Combination With Ribavirin in Chronic Hepatitis C (CHC) Patients With Compensated Liver Cirrhosis (LC)

Liver Cirrhosis | Chronic Hepatitis C

Japan
Miguel Santín

Completed

Study to Evaluate the Treatment for Chronic Hepatitis C With Normal Transaminases in HIV Positive Patients (CONTRA)

Chronic Hepatitis C

Spain
NORDynamIC Study Group

Completed

Multicenter Study Evaluating 12 Versus 24 Weeks Therapy With Peginterferon and Ribavirin for Hepatitis C Virus (HCV) Genotype 2 or 3

Hepatitis C Virus

Sweden
Germans Trias i Pujol Hospital
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la...

Completed

Viral Kinetics of Treatment With Peginterferon Alpha-2a, Ribavirin and Epoetin β in Patients Coinfected HCV/HIV

HIV Infections

Spain
Baqiyatallah Medical Sciences University
Shahid Beheshti University of Medical Sciences; Guilan University of Medical... and other collaborators

Completed

Pegasys® Plus Ribavirin in Hemophilic Patients With Hepatitis C Virus Infection

Hemophilia | Hepatitis C

Iran, Islamic Republic of
Hoffmann-La Roche

Withdrawn

A Study of the Safety of Individualized Combination Therapy With Copegus (Ribavirin) and Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C (MASTER)

Hepatitis C, Chronic
Hospital Carlos III, Madrid

Completed

Pilot Study of Patients Chronic Hepatitis C in Co-infected HIV Patients Relapsers After Previous Therapies (PILOT-NR)

HIV Infections | Chronic Hepatitis C

Spain
Vertex Pharmaceuticals Incorporated
Tibotec Pharmaceutical Limited

Completed

Safety and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects Co-Infected With Hepatitis C Virus (HCV) and HIV

HIV Infections | Hepatitis C

France, Spain, United States, Germany
ANRS, Emerging Infectious Diseases
Bristol-Myers Squibb

Completed

Therapy With Asunaprevir, Daclatasvir, Ribavirin and Pegylated Interferon Alpha-2a in HCV Genotype 4-infected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin (ANRS HC32 QUATTRO)

Hepatitis C Virus Genotype 4 Infection

France
University of Ulm
Hoffmann-La Roche

Completed

Influence of Antiviral Therapy on Bone Mineral Density and Metabolism in Patients With Chronic Hepatitis C

Liver Diseases | Virus Diseases | Hepatitis C, Chronic

Germany
Vertex Pharmaceuticals Incorporated
Tibotec Pharmaceutical Limited

Completed

A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response

Hepatitis C

Belgium, United States, Puerto Rico, Netherlands
Chang Gung Memorial Hospital

Terminated

Sustained Virological Response (SVR)Rate of Pegasys Plus Ribavirin in Patients With Chronic Hepatitis C

Chronic Hepatitis C

Taiwan
HealthCore-NERI
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Evaluating the Safety of Two Medications to Treat Hepatitis C in People With Thalassemia (The HepC Study) (HepC)

Hepatitis C | Thalassemia

United States, United Kingdom, Canada
Hoffmann-La Roche

Completed

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Ribavirin in Patients With Chronic Hepatitis C (CHC) Previously Treated With PEG-Intron + Ribavirin

Hepatitis C, Chronic

United States
Baqiyatallah Medical Sciences University
Guilan University of Medical Sciences; Baqiyatallah Research Center for Gastroenterology... and other collaborators

Completed

Pegasys® Plus Ribavirin in Thalassemic Patients With Hepatitis C Virus Infection

Hepatitis C | Thalassemia

Iran, Islamic Republic of
Hoffmann-La Roche

Completed

A Study of Setrobuvir in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Genotype 1 Chronic Hepatitis C

Hepatitis C, Chronic
Xiamen Amoytop Biotech Co., Ltd.
Peking University People's Hospital

Completed

Efficacy and Safety of Ypeginterferon Alfa-2b in Chronic Hepatitis C (PEGIFN)

Chronic Hepatitis C

China
Hoffmann-La Roche

Completed

A Study of The Relationship Between Drop in Hemoglobin and Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Copegus (Ribavirin) and Pegasys (Peginterferon Alfa-2a)

Hepatitis C, Chronic

Czech Republic
Merck Sharp & Dohme LLC

Completed

Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin (MK-2355-004)

Chronic Hepatitis C Infection
Merck Sharp & Dohme LLC

Completed

Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks (MK-2355-005)

Hepatitis C, Chronic
Hoffmann-La Roche

Completed

A Retrospective Study to Assess the Impact of the Use of Interferon in Patients With Chronic Hepatitis C (DECISION)

Hepatitis C, Chronic

Brazil
Hoffmann-La Roche

Completed

Peak Study - A Study of Pegasys (Peginterferon Alfa-2a (40KD)) in Combination With Copegus (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC).

Hepatitis C, Chronic

United States
National Institute of Diabetes and Digestive and...
National Cancer Institute (NCI); National Institute on Minority Health and... and other collaborators

Completed

Hepatitis C Antiviral Resistance in African-Americans

Hepatitis C

United States
Hoffmann-La Roche

Completed

A Study of Combination Therapy With PEGASYS (Pegylated Interferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response

Hepatitis C, Chronic

Belgium, United States, Germany, Canada, Austria, Switzerland, Puerto Rico, Australia, Brazil, Mexico
Janssen Pharmaceutical K.K.

Completed

A Phase III Study of TMC435 in Treatment-naive, Genotype 1, Hepatitis C-infected Patients

Hepatitis C, Chronic

Japan
Bristol-Myers Squibb

Completed

Study of BMS-650032 With Peginterferon Alfa-2a Plus Ribavirin

Hepatitis C Virus

France, Spain, United Kingdom, United States, Germany, Italy, Argentina, Ireland
Asan Medical Center
Samsung Medical Center; Seoul St. Mary's Hospital; Korea University Guro Hospital and other collaborators

Completed

Efficacy and Effectiveness of PegInterferon and Ribavirin in Korean Patients With Chronic Hepatitis C

Chronic Hepatitis C

Korea, Republic of
Bristol-Myers Squibb

Completed

Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir (PEDESTAL)

Hepatitis C Virus

Belgium, Germany, Spain, United States, Canada, Brazil, Austria, France, Israel, Switzerland, Italy, Russian Federation, Czechia, Poland, United Kingdom
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis

Chronic Hepatitis C Virus

United States, United Kingdom, Canada, Germany, Poland
Bristol-Myers Squibb

Completed

Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior Treatment (HEPCAT)

Hepatitis C Virus

Australia, France, Mexico, United States, Canada, Germany, Denmark, Italy, Puerto Rico, Sweden, Argentina
Mayo Clinic
Roche Pharma AG

Completed

Safety and Effectiveness Using Pegasys and Copegus in Recipients of Liver Transplantation With Hepatitis C

Hepatitis C | Liver Transplant

United States
Pusan National University Yangsan Hospital
Pusan National University Hospital; Inje University; Severance Hospital; Soon Chun... and other collaborators

Unknown

PegIFN Alfa-2a and RBV for 16 or 24 Weeks in Patients With Chronic Hepatitis C(CHC) 2 With Rapid Virologic Response(RVR)

Chronic Hepatitis C

Korea, Republic of
ANRS, Emerging Infectious Diseases
Janssen-Cilag Ltd.

Completed

Telaprevir in HIV-HCV Coinfected Patients Who Had Previously Failed a Peginterferon-Ribavirin Regimen (TelapreVIH)

HIV Infection | Hepatitis C, Chronic

France

3

Subscribe